These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34962532)

  • 21. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection.
    Darkes MJ; Plosker GL
    Paediatr Drugs; 2002; 4(9):609-30. PubMed ID: 12175274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Advisory Committee on Immunization Practices
    MMWR Recomm Rep; 2000 Oct; 49(RR-9):1-35. PubMed ID: 11055835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Meeting the challenge: prevention of pneumococcal disease with conjugate vaccines.
    Echániz-Avilés IG; Solórzano-Santos F
    Salud Publica Mex; 2001; 43(4):352-67. PubMed ID: 11547596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The rise and fall of pneumococcal serotypes carried in the PCV era.
    Devine VT; Cleary DW; Jefferies JM; Anderson R; Morris DE; Tuck AC; Gladstone RA; O'Doherty G; Kuruparan P; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2017 Mar; 35(9):1293-1298. PubMed ID: 28161425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population genomics of pneumococcal carriage in Massachusetts children following introduction of PCV-13.
    Mitchell PK; Azarian T; Croucher NJ; Callendrello A; Thompson CM; Pelton SI; Lipsitch M; Hanage WP
    Microb Genom; 2019 Feb; 5(2):. PubMed ID: 30777813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants.
    Yeh SH; Zangwill KM; Lee H; Chang SJ; Wong VI; Greenberg DP; Ward JI
    Vaccine; 2003 Jun; 21(19-20):2627-31. PubMed ID: 12744899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.
    Wagenvoort GH; Sanders EA; Vlaminckx BJ; de Melker HE; van der Ende A; Knol MJ
    Euro Surveill; 2017 Mar; 22(10):. PubMed ID: 28300529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Streptococcus pneumoniae pharyngeal colonization in school-age children and adolescents with cancer.
    Principi N; Preti V; Gaspari S; Colombini A; Zecca M; Terranova L; Cefalo MG; Ierardi V; Pelucchi C; Esposito S
    Hum Vaccin Immunother; 2016; 12(2):301-7. PubMed ID: 26367101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.
    Chen JJ; Yuan L; Huang Z; Shi NM; Zhao YL; Xia SL; Li GH; Li RC; Li YP; Yang SY; Xia JL
    BMJ Open; 2016 Oct; 6(10):e012488. PubMed ID: 27798013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.
    Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children.
    Ruiz-Contreras J; Picazo J; Casado-Flores J; Baquero-Artigao F; Hernández-Sampelayo T; Otheo E; Méndez C; Del Amo M; Balseiro C;
    Vaccine; 2017 Aug; 35(35 Pt B):4646-4651. PubMed ID: 28711388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of serotype-specific vaccination on phylodynamic parameters of Streptococcus pneumoniae and the pneumococcal pan-genome.
    Azarian T; Grant LR; Arnold BJ; Hammitt LL; Reid R; Santosham M; Weatherholtz R; Goklish N; Thompson CM; Bentley SD; O'Brien KL; Hanage WP; Lipsitch M
    PLoS Pathog; 2018 Apr; 14(4):e1006966. PubMed ID: 29617440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The safety and immunogenicity of an heptavalent pneumococcal polysaccharide conjugate vaccine (Prevenar) administered in association with a whole-cell pertussis-based pediatric combination vaccine (DTP-IPV/PRP-T) to French infants with a two-, three-, and four-month schedule].
    Reinert P; Guy M; Girier B; Szelechowski B; Baudoin B; Deberdt P; Wollner A; Kemeny G; Amzallag M; Moat C; Szelechowski C; Villain-Lemoine H; Bouhanna CA; Laudat F
    Arch Pediatr; 2003 Dec; 10(12):1048-55. PubMed ID: 14643532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation.
    Dagan R
    Expert Rev Vaccines; 2019 Jun; 18(6):641-661. PubMed ID: 31230486
    [No Abstract]   [Full Text] [Related]  

  • 35. Streptococcus pneumoniae serotype distribution in Vojvodina before the introduction of pneumococcal conjugate vaccines into the National Immunization Program.
    Petrović V; Šeguljev Z; Ristić M; Djekić-Malbaša J; Radosavljević B; Medić D; Mihajlović-Ukropina M; Hadnadjev M; Gajic I; Opavski N
    Srp Arh Celok Lek; 2016; 144(9-10):521-6. PubMed ID: 29653038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration.
    Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
    Vaccine; 2016 Aug; 34(36):4313-20. PubMed ID: 27422342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc analysis in a phase 3b, randomised, controlled trial.
    Safadi MAP; Martinon-Torres F; Weckx LY; Moreira ED; da Fonseca Lima EJ; Willemsen A; Toneatto D; Habib MA; Borys D
    Vaccine; 2019 Aug; 37(35):4858-4863. PubMed ID: 31327652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new conjugate vaccine against pneumococcal disease.
    Wilson-Adkins M; Adkins C
    Nurse Pract; 2001 May; 26(5):52, 55-6, 59-62. PubMed ID: 11383494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.
    Tan TQ
    Clin Microbiol Rev; 2012 Jul; 25(3):409-19. PubMed ID: 22763632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study.
    Namkoong H; Funatsu Y; Oishi K; Akeda Y; Hiraoka R; Takeshita K; Asami T; Yagi K; Kimizuka Y; Ishii M; Tasaka S; Suzuki Y; Iwata S; Betsuyaku T; Hasegawa N
    Vaccine; 2015 Jan; 33(2):327-32. PubMed ID: 25448102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.